Modern Rheumatology

, Volume 21, Issue 1, pp 16–23 | Cite as

Prevalence of reactivation of hepatitis B virus replication in rheumatoid arthritis patients

  • Yukitomo Urata
  • Ryoko Uesato
  • Dai Tanaka
  • Kenji Kowatari
  • Taisuke Nitobe
  • Yoshihide Nakamura
  • Shigeru Motomura
Original Article

Abstract

Reactivation of hepatitis B involves the reappearance of active necroinflammatory liver disease after an inactive hepatitis B surface antigen (HBsAg) carrier state or resolved hepatitis B, occurring during or after immunosuppression therapy or chemotherapy. We prospectively investigated the reactivation rate for hepatitis B virus (HBV) DNA replication in cases of rheumatoid arthritis (RA) with resolved hepatitis B. HBV markers were evaluated in 428 RA patients. Patients with positive findings of HBsAg or HBV DNA at enrolment were excluded. The study population comprised 422 RA patients, with resolved hepatitis B diagnosed in 135 patients based on HBsAg-negative and antihepatitis B core antibody/antihepatitis B surface antibody-positive results. HBV DNA was measured every 3 months in this group, and if HBV DNA became positive after enrolment, measurement was repeated every month. HBV DNA became positive (≥3.64 log copies/mL) in 7 of 135 patients for 12 months. Use of biologic agents was significantly more frequent in patients who developed reactivation of HBV DNA replication (85.7%) than in patients who did not (36.0%, p = 0.008). Hazard ratios for use of biologic agents and etanercept were 10.9 (p = 0.008) and 6.9 (p = 0.001), respectively. RA patients with resolved hepatitis B need careful monitoring when receiving biologic agents, regardless of HBV DNA levels.

Keywords

Biologic Hepatitis B virus Reactivation of hepatitis B Rheumatoid arthritis 

Notes

Conflict of interest

None.

References

  1. 1.
    Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009;50:61–2.Google Scholar
  2. 2.
    Di Bisceglie AM. Hepatitis B and hepatocellular carcinoma. Hepatology. 2009;49:S56–60.CrossRefPubMedGoogle Scholar
  3. 3.
    Hoofnagle JH. Reactivation of hepatitis B. Hepatology. 2009;49:S156–65.CrossRefPubMedGoogle Scholar
  4. 4.
    Calabrese LH, Zein NN, Vassilopoulos D. Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies. Ann Rheum Dis. 2006;65:983–9.CrossRefPubMedGoogle Scholar
  5. 5.
    Zingarelli S, Airò P, Frassi M, Bazzani C, Scarsi M, Puoti M. Prophylaxis and therapy of HBV infection in 20 patients treated with disease modifying antirheumatic drugs or with biological agents for rheumatic diseases. Reumatismo. 2008;60:22–7.PubMedGoogle Scholar
  6. 6.
    Ostuni P, Botsios C, Punzi L, Sfriso P, Todesco S. Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate. Ann Rheum Dis. 2003;62:686–7.CrossRefPubMedGoogle Scholar
  7. 7.
    Cansu DU, Kalifoglu T, Korkmaz C. Short-term course of chronic hepatitis B and C under treatment with etanercept associated with different disease modifying antirheumatic drugs without antiviral prophylaxis. J Rheumatol. 2008;35:421–4.PubMedGoogle Scholar
  8. 8.
    Zoulim F. New insight on hepatitis B virus persistence from the study of intrahepatic viral cccDNA. J Hepatol. 2005;42:302–8.CrossRefPubMedGoogle Scholar
  9. 9.
    Rehermann B, Ferrari C, Pasquinelli C, Chisari FV. The hepatitis B virus persists for decades after patients’ recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med. 1996;2:1104–8.CrossRefPubMedGoogle Scholar
  10. 10.
    Yuki N, Nagaoka T, Yamashiro M, Mochizuki K, Kaneko A, Yamamoto K, et al. Long-term histologic and virologic outcomes of acute self-limited hepatitis B. Hepatology. 2003;37:1172–9.CrossRefPubMedGoogle Scholar
  11. 11.
    Yeo W, Johnson PJ. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology. 2006;43:209–20.CrossRefPubMedGoogle Scholar
  12. 12.
    Kitano K, Kobayashi H, Hanamura M, Furuta K, Ueno M, Rokuhara A, et al. Fulminant hepatitis after allogenic bone marrow transplantation caused by reactivation of hepatitis B virus with gene mutations in the core promoter region. Eur J Haematol. 2006;77:255–8.CrossRefPubMedGoogle Scholar
  13. 13.
    Hui CK, Cheung WW, Zhang HY, Au WY, Yueng YH, Leung AY, et al. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology. 2006;131:59–68.CrossRefPubMedGoogle Scholar
  14. 14.
    Sera T, Hiasa Y, Michitaka K, Konishi I, Matsuura K, Tokumoto Y, et al. Anti-HBs-positive liver failure due to hepatitis B virus reactivation induced by rituximab. Intern Med. 2006;45:721–4.CrossRefPubMedGoogle Scholar
  15. 15.
    Esteve M, Saro C, González-Huix F, Suarez F, Forné M, Viver JM. Chronic hepatitis B reactivation following infliximab therapy in Crohn’s disease patients: need for primary prophylaxis. Gut. 2004;53:1363–5.CrossRefPubMedGoogle Scholar
  16. 16.
    Ito S, Nakazono K, Murasawa A, Mita Y, Hata K, Saito N, et al. Development of fulminant hepatitis B (precore variant mutant type) after the discontinuation of low-dose methotrexate therapy in a rheumatoid arthritis patient. Arthritis Rheum. 2001;44:339–42.CrossRefPubMedGoogle Scholar
  17. 17.
    Montiel PM, Solis JA, Chirinos JA, Casis B, Sánchez F, Rodríguez S. Hepatitis B virus reactivation during therapy with etanercept in an HBsAg-negative and anti-HBs-positive patient. Liver Int. 2008;28:718–20.CrossRefPubMedGoogle Scholar
  18. 18.
    Madonia S, Orlando A, Scimeca D, Olivo M, Rossi F, Cottone M. Occult hepatitis B and infliximab-induced HBV reactivation. Inflamm Bowel Dis. 2007;13:508–9.CrossRefPubMedGoogle Scholar
  19. 19.
    Sasaki S, Sato S, Kano Y, et al. Validity of COBAS TaqMan HBV Test v2.0. Igaku to Yakugaku. 2009;61:787–95 (in Japanese).Google Scholar
  20. 20.
    Raimondo G, Pollicino T, Cacciola I, Squadrito G. Occult hepatitis B virus infection. J Hepatol. 2007;46:160–70.CrossRefPubMedGoogle Scholar
  21. 21.
    Togashi H, Hashimoto C, Yokozawa J, Suzuki A, Sugahara K, Saito T, et al. What can be revealed by extending the sensitivity of HBsAg detection to below the present limit? J Hepatol. 2008;49:17–24.CrossRefPubMedGoogle Scholar
  22. 22.
    Liang R, Lau GK, Kwong YL. Chemotherapy and bone marrow transplantation for cancer patients who are also chronic hepatitis B carriers: a review of the problem. J Clin Oncol. 1999;17:394–8.PubMedGoogle Scholar
  23. 23.
    Lalazar G, Rund D, Shouval D. Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies. Br J Haematol. 2007;136:699–712.CrossRefPubMedGoogle Scholar
  24. 24.
    Lau GK. Hepatitis B reactivation after chemotherapy: two decades of clinical research. Hepatol Int. 2008;2:152–62.CrossRefPubMedGoogle Scholar
  25. 25.
    Lubel JS, Testro AG, Angus PW. Hepatitis B virus reactivation following immunosuppressive therapy: guidelines for prevention and management. Intern Med J. 2007;37:705–12.CrossRefPubMedGoogle Scholar
  26. 26.
    Bradley JR. TNF-mediated inflammatory disease. J Pathol. 2008;214:149–60.CrossRefPubMedGoogle Scholar
  27. 27.
    Harris ED Jr. Rheumatoid arthritis. Pathophysiology and implications for therapy. N Engl J Med. 1990;322:1277–89.CrossRefPubMedGoogle Scholar
  28. 28.
    Gibbons LJ, Hyrich KL. Biologic therapy for rheumatoid arthritis: clinical efficacy and predictors of response. BioDrug. 2009;23:111–24.CrossRefGoogle Scholar
  29. 29.
    Winthrop KL. Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor. Nat Clin Pract Rheumatol. 2006;2:602–10.CrossRefPubMedGoogle Scholar
  30. 30.
    Daniels HM, Meager A, Eddleston AL, Alexander GJ, Williams R. Spontaneous production of tumour necrosis factor alpha and interleukin-1 beta during interferon-alpha treatment of chronic HBV infection. Lancet. 1990;335:875–7.CrossRefPubMedGoogle Scholar
  31. 31.
    Fang JW, Shen WW, Meager A, Lau JY. Activation of the tumor necrosis factor-alpha system in the liver in chronic hepatitis B virus infection. Am J Gastroenterol. 1996;91:748–53.PubMedGoogle Scholar
  32. 32.
    Stoop JN, Woltman AM, Biesta PJ, Kusters JG, Kuipers EJ, Janssen HL, et al. Tumor necrosis factor alpha inhibits the suppressive effect of regulatory T cells on the hepatitis B virus-specific immune response. Hepatology. 2007;46:699–705.CrossRefPubMedGoogle Scholar
  33. 33.
    Wong GH, Goeddel DV. Tumour necrosis factors alpha and beta inhibit virus replication and synergize with interferons. Nature. 1986;323:819–22.CrossRefPubMedGoogle Scholar
  34. 34.
    Kasahara S, Ando K, Saito K, Sekikawa K, Ito H, Ishikawa T, et al. Lack of tumor necrosis factor alpha induces impaired proliferation of hepatitis B virus-specific cytotoxic T lymphocytes. J Virol. 2003;77:2469–76.CrossRefPubMedGoogle Scholar
  35. 35.
    Ganem D, Prince AM. Hepatitis B virus infection—natural history and clinical consequences. N Engl J Med. 2004;350:1118–29.CrossRefPubMedGoogle Scholar
  36. 36.
    Herbein G, O’Brien WA. Tumor necrosis factor (TNF)-alpha and TNF receptors in viral pathogenesis. Proc Soc Exp Biol Med. 2000;223:241–57.CrossRefPubMedGoogle Scholar
  37. 37.
    Guidotti LG, Ishikawa T, Hobbs MV, Matzke B, Schreiber R, Chisari FV. Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity. 1996;4:25–36.CrossRefPubMedGoogle Scholar
  38. 38.
    Marinos G, Naoumov NV, Rossol S, Torre F, Wong PY, Gallati H, et al. Tumor necrosis factor receptors in patients with chronic hepatitis B virus infection. Gastroenterology. 1995;108:1453–63.CrossRefPubMedGoogle Scholar
  39. 39.
    Chung SJ, Kim JK, Park MC, Park YB, Lee SK. Reactivation of hepatitis B viral infection in inactive HBsAg carriers following anti-tumor necrosis factor-alpha therapy. J Rheumatol. 2009;36:2416–20.CrossRefPubMedGoogle Scholar
  40. 40.
    Millonig G, Kern M, Ludwiczek O, Nachbaur K, Vogel W. Subfulminant hepatitis B after infliximab in Crohn’s disease: need for HBV-screening? World J Gastroenterol. 2006;14:974–6.Google Scholar
  41. 41.
    Michel M, Duvoux C, Hezode C, Cherqui D. Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset still’s disease. J Rheumatol. 2003;30:1624–5.PubMedGoogle Scholar
  42. 42.
    Wendling D, Auge B, Bettinger D, Lohse A, Le Huede G, Bresson-Hadni S, et al. Reactivation of a latent precore mutant hepatitis B virus related chronic hepatitis during infliximab treatment for severe spondyloarthropathy. Ann Rheum Dis. 2005;64:788–9.CrossRefPubMedGoogle Scholar
  43. 43.
    Kaur PP, Chan VC, Berney SN. Histological evaluation of liver in two rheumatoid arthritis patients with chronic hepatitis B and C treated with TNF-alpha blockade: case reports. Clin Rheumatol. 2008;27:1069–71.CrossRefPubMedGoogle Scholar
  44. 44.
    Sakellariou GT, Chatzigiannis I. Long-term anti-TNFalpha therapy for ankylosing spondylitis in two patients with chronic HBV infection. Clin Rheumatol. 2007;26:950–2.CrossRefPubMedGoogle Scholar
  45. 45.
    Nishimoto N, Kishimoto T. Interleukin 6: from bench to bedside. Nat Clin Pract Rheumatol. 2006;2:619–26.CrossRefPubMedGoogle Scholar
  46. 46.
    Kakumu S, Shinagawa T, Ishikawa T, Yoshioka K, Wakita T, Ito Y, et al. Serum interleukin 6 levels in patients with chronic hepatitis B. Am J Gastroenterol. 1991;86:1804–8.PubMedGoogle Scholar
  47. 47.
    Yeo W, Chan TC, Leung NW, Lam WY, Mo FK, Chu MT, et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol. 2009;27:605–11.CrossRefPubMedGoogle Scholar
  48. 48.
    Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, et al. REVEAL-HBV Study Group. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006;295:65–73.CrossRefPubMedGoogle Scholar

Copyright information

© Japan College of Rheumatology 2010

Authors and Affiliations

  • Yukitomo Urata
    • 1
  • Ryoko Uesato
    • 2
  • Dai Tanaka
    • 2
  • Kenji Kowatari
    • 2
  • Taisuke Nitobe
    • 2
  • Yoshihide Nakamura
    • 3
  • Shigeru Motomura
    • 4
  1. 1.Department of RheumatologySeihoku Chuo HospitalGosyogawaraJapan
  2. 2.Department of Orthopaedic SurgerySeihoku Chuo HospitalGosyogawaraJapan
  3. 3.Department of Orthopaedic SurgeryHirosaki University Graduate School of MedicineHirosakiJapan
  4. 4.Department of PharmacologyHirosaki University Graduate School of MedicineHirosakiJapan

Personalised recommendations